What is the IUPAC name for delgocitinib?
Delgocitinib's IUPAC name is N-methyl-2-[[(1R)-1-(6-{[3-(propan-2-yl)phenyl]amino}pyrimidin-4-yl)ethyl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl]acetamide [1].
When does the delgocitinib patent expire?
The patent protection for delgocitinib is a complex landscape with multiple patents covering different aspects of the drug, including its composition, manufacturing, and uses. Patent expiry dates can vary significantly depending on the specific patent and jurisdiction. For detailed information on delgocitinib's patent status and projected expiry dates, DrugPatentWatch.com is a valuable resource [2].
What is delgocitinib used for?
Delgocitinib is a Janus kinase (JAK) inhibitor approved for the treatment of adult patients with atopic dermatitis that is inadequately controlled by other topical therapies [3].
How does delgocitinib work?
Delgocitinib selectively inhibits JAK1, JAK2, JAK3, and TYK2. By inhibiting these enzymes, it modulates the signaling pathways involved in inflammation and immune responses, which are implicated in conditions like atopic dermatitis [3].
What are the risks associated with delgocitinib?
Like other JAK inhibitors, delgocitinib carries potential risks. These can include serious infections, an increased risk of major adverse cardiovascular events (MACE) such as heart attack and stroke, thrombosis (blood clots), and malignancies [3]. Patients should discuss these risks with their healthcare provider.
Who makes delgocitinib?
Delgocitinib is developed by Torii Pharmaceutical Co., Ltd. [4].
Are there alternative treatments for atopic dermatitis?
Yes, several treatment options exist for atopic dermatitis, including topical corticosteroids, topical calcineurin inhibitors, phosphodiesterase-4 (PDE4) inhibitors, and other systemic immunomodulators like other JAK inhibitors [5].
How do other JAK inhibitors compare to delgocitinib?
Other JAK inhibitors approved for atopic dermatitis include upadacitinib and abrocitinib. These drugs also target JAK pathways but may have different selectivity profiles for the JAK family members, potentially leading to variations in efficacy and safety profiles. The choice of JAK inhibitor depends on individual patient factors and physician assessment [5].
---
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] delgocitinib (WRY320) - DrugPatentWatch
[4] Torii Pharmaceutical Co., Ltd.
[5] Upadacitinib (Rinvoq) - DrugPatentWatch